16066-97-0Relevant articles and documents
Combination of a beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity
Jesudason, Cynthia D.,Baker, James E.,Bryant, Robert D.,Fisher, Jack W.,O'Farrell, Libbey S.,Gaich, Gregory A.,He, Minxia M.,Kahl, Steven D.,Kriauciunas, Aidas V.,Heiman, Mark L.,Peters, Mary A.,Rito, Christopher J.,Satterwhite, Julie H.,Tinsley, Frank C.,Trankle, William G.,Shuker, Anthony J.
, p. 583 - 586 (2011)
We report the novel combination of a selective beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor (sibutramine) with potential for the treatment of obesity. The synthesis and characterization of 6-[4-[2-[[(2S)-3-(9H-carbazol-4-ylo
BENZOTHIAZOLONE COMPOUND
-
Paragraph 38; 39, (2013/03/26)
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form(I) a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination o
(ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES
-
Page/Page column 76, (2012/10/08)
Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula 1, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases